# BWX Technologies, Inc. (BWXT) — InvestMoat Analysis

_Last analyzed: October 11, 2026_
_Asset class: equity · Canonical page: https://investmoat.com/stocks/bwxt_

## Scores

| Dimension | Score (0–100) |
| --- | --- |
| Moat durability | 80 |
| Growth trajectory | 69 |
| Valuation | 77 |
| **Composite** | **77** |

Scores are computed deterministically from this asset’s data by the InvestMoat formula (see https://investmoat.com/llms.txt for methodology). Scores are not directly comparable across asset classes.

## Key stats

- **Ticker:** BWXT
- **Market Cap:** ~$13.2B

## Moat

BWXT is the sole manufacturer of the reactors and naval fuel for every US Navy nuclear-powered submarine and aircraft carrier, and owns both of the only two privately held NRC Category I facilities licensed to store and process highly enriched uranium, a franchise funded under multi-year Naval Nuclear Propulsion Program contracts that no rival can bid for.

### The Naval Reactor Monopoly

BWXT's moat is **a government-sanctioned monopoly on naval nuclear propulsion hardware and highly enriched uranium processing**:

- **Sole Supplier to the Naval Nuclear Propulsion Program:** BWXT manufactures the reactor components and the naval fuel (through Nuclear Fuel Services in Erwin, Tennessee) for the Virginia- and Columbia-class submarines and the Ford-class carriers, and its reactors power the Ohio, Seawolf, Los Angeles and Nimitz classes already in service. The Navy funds that work through multi-year contracts: about $2.1B of reactor-component awards in February 2025 and more than $1.4B in May 2026, the larger piece the first of five annual task orders available through 2030. There is no second source to re-compete with, so the contract flow is set by shipbuilding schedules, not by bids.
- **Two of Two Category I HEU Licences:** The Lynchburg, Virginia site and the Erwin, Tennessee site are the only two privately owned NRC Category I facilities licensed to store and process highly enriched uranium. That is why the NNSA routes HEU purification, conversion and downblending work to BWXT, and why the special-materials line and the HALEU downblending capability sit in the same company as the naval business. A new entrant would need security infrastructure, a Category I licence and the Navy's qualification, and none has tried.
- **A Commercial Leg That Is Growing Faster:** Commercial Operations (CANDU steam generators and components, field services, fuel handling, the Kinectrics engineering and testing business and, from July 2026, Precision Components Group) grew 72% in Q2 2026, 33% organically, and management guides the segment to roughly 45% growth for 2026. It is a real but contested business, competing with Framatome, Westinghouse and Curtiss-Wright, and the medical isotope unit is being sold to Nordic Capital for up to $800M, which narrows BWXT back to nuclear components, fuel and services.

**Moat verdict:** BWXT is a modest net beneficiary of AI: data-centre power demand supports the commercial nuclear new-build and refurbishment cycle its Commercial Operations segment sells into, while nothing in its core work can be automated away. Its moats, the two Category I HEU licences and sole-source naval reactor embedding, are physical and regulatory and fully AI-resilient; the AI-vulnerable pillars are mostly inapplicable, and the real risks are budget timing and shipyard schedules, not technology.

### Top competitors

- **Framatome:** EDF's nuclear equipment and fuel arm, competing for commercial reactor components and services.
- **Westinghouse Electric:** Reactor vendor and fuel supplier, co-owned by Cameco and Brookfield, competing in commercial components, fuel and outage services.
- **Curtiss-Wright (CW):** Naval nuclear pumps and valves plus commercial nuclear components; a supplier around the reactor rather than of it.
- **[Centrus Energy (LEU)](https://investmoat.com/stocks/leu):** Rival for DOE enrichment and HALEU fuel-supply work.

## Growth

Q2 2026 revenue rose 18% to $901.6M (9% organic): Government Operations grew 2% to $601.3M on naval propulsion and special materials, partly offset by lower advanced-nuclear volume, while Commercial Operations rose 72% to $302.5M (33% organic) on commercial nuclear components, field services and Kinectrics. Adjusted EBITDA rose only 7% to $155.5M, so the quarter's margin fell on mix and Government Operations operating income slipped 3% to $105.7M. Management raised 2026 guidance to ~$3.8B revenue, $662–672M adjusted EBITDA, $4.70–4.80 non-GAAP EPS and $345–360M free cash flow, and at its September 29 Investor Day set 2030 targets of $5.5–6.0B revenue and $1.1–1.2B adjusted EBITDA (about 20% margin from 17.5% in 2026).

- **Revenue CAGR estimate:** 9-13%
- **Primary type:** both
- **Margin trend:** stable
- **Key risk (moderate):** If FY2027 defense appropriations run on an extended continuing resolution, or Columbia- and Virginia-class build rates slip further at the shipyards through 2027, naval component deliveries convert from the $8.4B backlog more slowly and the 2030 revenue target of $5.5–6.0B moves out of reach.
- **Drivers:**
  - Commercial Operations (components, field services, Kinectrics, PCG) — Q2 2026 revenue $302.5M, +72% YoY (+33% organic); segment operating income $24.3M vs $6.9M; FY2026 segment growth guided ~45% (accelerating)
  - Naval propulsion and special materials (Government Operations) — Q2 2026 Government Ops revenue $601.3M, +2% YoY; $1.4B NNPP awards in May 2026 after ~$2.1B in February 2025 (stable)
  - Advanced nuclear (government microreactors and space programmes) — Lower volume partly offset Government Ops growth in Q2 2026 (decelerating)
- **Score derivation:** Base 74.3 (9–13% CAGR, midpoint 11%) + 0 trajectory (Commercial Ops accelerating, naval propulsion and special materials stable, advanced nuclear decelerating) + 0 stable margin (FY2026 adjusted EBITDA margin guide ~17.5% against ~17.9% in 2025; Q2's dip is acquisition mix, and the 2030 ~20% target is not yet in the numbers) − 5 moderate keyRisk (defense appropriations timing, graded with LMT, which shares the budget risk; lower than CCJ and LEU because BWXT's demand is funded naval programmes rather than uranium prices or SMR deployment) = 69

## Valuation

At ~$143.83 (October 9, 2026 close), down about 40% from the $241.82 52-week high after estimate cuts and a sector de-rating rather than an operating miss, BWXT trades at ~30× the $4.70–4.80 FY2026 EPS guide and ~28× FY2027 consensus of ~$5.18. The ladder is struck on FY2027 EPS of ~$5.20: bear $115 (~22×), base $170 (~33×, near the multiple the stock held before the run-up) and bull $240 (a return to the high, ~40× an FY2028 that tracks the 2030 targets). The price sits ~25% above bear and ~15% below base. The base sits well below the Street (~$225 median), which is still anchored on pre-drawdown multiples; LMT, the closest defense comparator, is struck at ~20× and the gap is the sole-source naval franchise and faster growth.

**Fair value:** $170 — Net debt was about $1.4B at June 30, 2026 (~$608M cash against ~$2.02B long-term debt), before the up-to-$800M medical sale expected to close by year-end. At ~$143.83 the risk/reward is roughly 20% downside to bear ($115) against 18% upside to base ($170) and 67% to bull ($240).

| Multiple | Value | Note |
| --- | --- | --- |
| Forward P/E (FY2026 guide) | ~30× | $4.70–4.80 non-GAAP EPS guide |
| Forward P/E (FY2027) | ~28× | consensus EPS est. ~$5.18 |
| PEG Ratio | ~2.3× | fwd P/E ÷ ~12% EPS CAGR |
| Price / Sales | ~3.5× | ~$3.8B FY2026 revenue guide |
| Price / FCF | ~37× | $345–360M FY2026 FCF guide |

At ~28× FY2027 earnings BWXT is expensive against defense primes (LMT ~17×) but no longer against its own history after a 40% drawdown. A PEG near 2.3× says the multiple still pays for scarcity, not for growth alone; the low-teens revenue path to 2030 with margin expansion toward 20% is what has to carry it. Earnings are guided to grow faster than revenue, so the forward multiple compresses if the 2030 targets hold. _(as of October 2026 (price ~$143.83))_

## Price scenarios

### Bear — $115

Defense budget friction and slower submarine build rates stretch naval deliveries, the commercial segment's acquired growth fades into a high-single-digit organic rate, and the market pays a defense-contractor multiple of about 22× FY2027 EPS.

- An extended FY2027 continuing resolution or a Columbia/Virginia schedule slip at General Dynamics Electric Boat and HII pushes naval component revenue growth to low single digits through 2027
- Commercial Operations organic growth slows below 10% once Kinectrics and PCG are lapped, as Canadian refurbishment work peaks and new-build orders stay slow
- Adjusted EBITDA margin stays near 17.5% instead of moving toward the 20% 2030 target, and FY2027 EPS lands closer to $5.00 than $5.20

### Base — $170

Naval propulsion compounds on funded multi-year contracts, Commercial Operations grows double digits, FY2027 EPS reaches about $5.20, and the stock re-rates to about 33× as the drawdown's estimate cuts prove smaller than feared.

- Annual NNPP task orders under the May 2026 award (first of five through 2030) are exercised on schedule and Government Operations returns to mid-to-high single-digit growth
- Commercial Operations delivers its ~45% 2026 guide and double-digit organic growth in 2027 on CANDU refurbishment, field services and PCG
- The medical sale closes by year-end, adding up to $800M of proceeds that cut net debt of ~$1.4B or fund nuclear capacity

### Bull — $240

The AUKUS and US submarine build-up, new HEU and enrichment work for the NNSA, and a commercial new-build cycle push BWXT ahead of its 2030 path, and the stock regains its 52-week high at about 40× FY2028 earnings.

- Submarine build rates rise toward the Navy's two-Virginia-plus-one-Columbia goal, lifting reactor-component and fuel volume above the 2030 plan
- Special materials and defense enrichment awards expand the Government Operations backlog well beyond $8.4B
- Commercial reactor new-builds in Canada and the US turn into component orders, and adjusted EBITDA margin reaches ~20% ahead of 2030

---

InvestMoat is a research and education framework. Nothing here is financial advice. Past performance does not guarantee future results.